Use of Ziv Aflibercept in Different Retinal Diseases

Amin El Sayed Nawar55 enrolled

Overview

A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.

Intravitreal injection of 1.25 mg of ziv aflibercept was done in different retinal diseases including myopic CVN,resistant diabetic macular edema to previous ranibizumab injection and non ischaemic CRVO .Thorough ophthalmic evaluation was done including BCVA(best corrected visual acuity) ,anterior and posterior segment examination ,fundus fluorescein angiography and OCT(optical coherence tomography) were performed for all patients .Injection was repeated as PRN(pro re nata) method after one month if persistent intraretinal or subretinal fluid was found.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Central Retinal Vein Occlusion With Macular Edema

Interventions

Ziv-Aflibercept 25 MG/ML [Zaltrap]DRUG

Intravitreal injection of 1.25 mg of ziv aflibercept in patients

Eligibility

Sex: ALLMin age: 31 YearsMax age: 63 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The study included treatment naive patients suffering from recently diagnosed active myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological myopia more than 6 D was included . Exclusion Criteria: * Previous intraocular surgery . * Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion . * CNV due to other causes like age related macular degeneration ,angioid streaks,trauma and choroiditis. * Extrafoveal myopic CNV . * Patients received other lines of treatment for CNV like photodynamic therapy ,laser photocoagulation or intravitreal injection of triamcinolone or other anti VEGF(vascular endothelial growth factor) agents. * Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than 20 mmHg. * Prior ocular inflammation. * The presence of retinal degeneration. * Patients who didnot complete 6 months of follow up

Locations (1)

Tanta University

Tanta, El Gharbia, Egypt

Outcomes

Primary Outcomes

Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection

To assess sustained improvement of BCVA(Best corrected visual acuity) and reduction of the CMT (central macular thickness) after intravitreal injection of zivaflibercept

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.